Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, and will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results. A replay will be available on the company’s Investor Relations website.
Caris Life Sciences (NASDAQ: CAI) announced it will offer in-house PTEN immunohistochemistry (IHC) testing for metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer, following recent FDA approval of a PTEN biomarker-guided therapy and companion diagnostic assay. The assay is intended to identify PTEN-deficient tumors, which occur in about one in four patients with this disease and are linked to faster progression and poorer outcomes.
According to Caris, PTEN IHC testing will be run in its CAP-accredited, CLIA-certified labs to support faster results, integrate with its multi-platform molecular profiling (including NGS), and expand its broader portfolio of assays such as MI Cancer Seek, Caris Assure, Caris MI Clarity, Caris Chromoseq and Caris Detect.
Caris Life Sciences (NASDAQ: CAI) announced the commercial launch of Caris Detect, a multi-cancer early detection blood test using ultra-deep Whole Genome and Whole Transcriptome sequencing combined with AI.
The test analyzes DNA, RNA and other molecular signals, leveraging a database of over one million cases and 50 billion markers. Data from the Caris Detect ACHIEVE 1 study showed strong performance across multiple cancer types. Caris plans further research and future study milestones to expand capabilities over time.
Caris Life Sciences (NASDAQ: CAI) announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. Shares will keep trading on NASDAQ and also list on NYSE Texas under the CAI ticker, aiming for greater investor exposure, especially in Texas.
Caris Life Sciences (Nasdaq: CAI) announced that its board authorized a share repurchase program for up to $100 million of outstanding common stock. Repurchases may occur via open market, privately negotiated deals, or Rule 10b5-1 trading plans and will follow Rule 10b-18 requirements.
The program has no expiration date, does not require any minimum repurchases, and can be modified, suspended, or discontinued at any time. Caris currently expects to fund buybacks using available cash and cash equivalents.
Caris Life Sciences (NASDAQ: CAI) launched the “Behind the Diagnosis” campaign highlighting real patients whose treatment was informed by Caris’ comprehensive genomic profiling and AI.
The first story features Caris GPSai correcting a presumed metastatic breast cancer to highly treatable Hodgkin lymphoma, and references FDA-approved MI Cancer Seek and clinical data on GPSai’s impact on misdiagnosis and therapy eligibility.
Caris Life Sciences (NASDAQ: CAI) published a study in The Oncologist on the Caris Lookback Program, which continuously re-evaluates prior Caris MI Cancer Seek tests as new biomarker‑drug approvals emerge.
From >483,000 profiles, the program found 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types, about 40% in non‑small cell lung cancer, using multi‑modal profiling such as WES, WTS and IHC. MI Cancer Seek is described as the first and only simultaneous WES+WTS‑based assay with FDA‑approved CDx indications for solid tumors, available for adults and children aged 1 and older.
Caris Life Sciences (NASDAQ:CAI) reported study results showing that ultra-deep Whole Exome Sequencing (WES) measurement of tumor mutational burden (TMB) better predicts pembrolizumab benefit than targeted gene panels.
Among 26,756 pembrolizumab-treated patients, targeted panels misclassified TMB in 10–15% of cases, while WES-based TMB was linked to longer overall survival in key subgroups.
Caris’ FDA-approved MI Cancer Seek assay delivers simultaneous WES and Whole Transcriptome Sequencing with quantitative TMB reporting for solid tumors.
Caris Life Sciences (NASDAQ: CAI) submitted an application to the New York State Department of Health CLEP/Wadsworth Center to seek authorization to perform Caris Assure blood-based molecular profiling on specimens from New York State patients.
Caris Assure uses circulating nucleic acids sequencing to analyze the whole exome and whole transcriptome of 22,000 genes, reporting tumor alterations, clonal hematopoiesis, inherited variants, pharmacogenomics, MSI and TMB. Authorization is pending; Caris will only test New York specimens if CLEP approval is granted.
Caris Life Sciences (Nasdaq: CAI) reported Q1 2026 results for the quarter ended March 31, 2026. Total revenue $216.2M, up 79% year‑over‑year; molecular profiling revenue $210.8M. Reported gross margin 65%, net loss $0.5M, and Adjusted EBITDA $26.2M. Q1 operating cash flow was $32.9M; free cash flow $22.5M. Company reaffirmed 2026 revenue guidance of $1.0–$1.02B and ~20% clinical therapy selection volume growth.
Operational highlights include ~52,800 clinical therapy selection cases, Achieve 1 study results, new assay launches, and a $400M refinanced credit facility.